Novel mechanisms of endothelial dysfunction in diabetes

Guang Yang1, Rudolf Lucas1,2, Ruth Caldwell2, Lin Yao2, Maritza J. Romero2, Robert W. Caldwell2
1Vascular Biology Center, 2Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, GA, USA

Address for correspondence: Dr. Rudolf Lucas, Vascular Biology Center & Department of Pharmacology and Toxicology, Augusta, GA, USA. E-mail: rlucas@mcg.edu

ABSTRACT

Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality. This condition increases the risk of developing coronary, cerebrovascular, and peripheral arterial disease fourfold. Endothelial dysfunction is a major contributor to the pathogenesis of vascular disease in diabetes mellitus patients and has recently received increased attention. In this review article, some recent developments that could improve the knowledge of diabetes-induced endothelial dysfunction are discussed.

Key words: Arginase, diabetes, endothelial dysfunction, protein kinase C, reactive oxygen species, tumor necrosis factor

DOI: 10.4103/0975-3583.64432

INTRODUCTION

According to the World Health Organization, diabetes mellitus now affects about 220 million people worldwide,[1] and the growth in its prevalence represents a global health crisis already accounting for more than 10% of the total healthcare expenditure in many countries.[2] In the USA, over 24 million children and adults (almost 8% of the entire population) have diabetes, whereas another 57 million have prediabetes and are thus likely to develop the disease unless they make lifestyle changes.[3] Diabetes without proper treatment can cause many complications, with cardiovascular diseases accounting for up to 80% of premature mortality.[4]

The endothelium, once considered a mere selectively permeable barrier between the bloodstream and the outer vascular wall, is now recognized to be a crucial homeostatic organ, fundamental for the regulation of the vascular tone and structure.[5] Therefore, endothelial dysfunction during diabetes has been associated with a number of pathophysiologic processes.[6] A considerable body of evidence in humans indicates that endothelial dysfunction is closely associated with the development of diabetic retinopathy,[7] nephropathy, and atherosclerosis in both type 1 and type 2 diabetes.[8] In this article, the recent findings on the mechanisms of endothelial dysfunction in diabetes, which could contribute to the development of new treatment options are discussed.

PHYSIOLOGIC ROLE OF THE VASCULAR ENDOTHELIUM

The healthy endothelial monolayer is optimally positioned in order to respond to physical and chemical signals, by producing a wide range of factors that regulate vascular tone, cellular adhesion, thromboresistance, smooth muscle cell proliferation, and vessel wall inflammation. The importance of the endothelium was first recognized by its effect in limiting the vascular tone.[9] The vascular endothelium also regulates blood flow and, limits leukocyte adhesion and platelet aggregation by producing nitric oxide (NO), prostacyclin, and ectonucleotidases. As such, inflammatory activity in the vessel wall is blunted. In addition, the endothelium regulates vascular permeability to nutrients, macromolecules, and leukocytes; limits activation of the coagulation cascade by the thrombomodulin/protein C, heparin sulfate/antithrombin, and tissue factor/tissue factor pathway inhibitor interactions; and regulates fibrinolysis by producing tissue activator of plasminogen (t-PA) and its inhibitor, PAI-1.[10]
The term endothelial dysfunction refers to a condition in which the endothelium loses its physiologic properties and shifts toward a vasoconstrictor, prothrombotic, and proinflammatory state.[11] Endothelial dysfunction has been associated with a variety of processes, including hypertension, atherosclerosis, aging, heart and renal failure, coronary syndrome, obesity, vasculitis, infections, sepsis, rheumatoid arthritis, thrombosis, smoking as well as with type 1 and type 2 diabetes.[4]

Diabetes mellitus, often simply referred to as diabetes, is a condition with elevated blood glucose levels, as a result of either the body not producing enough insulin, or because cells do not properly respond to the insulin that is produced. The latter condition is characterized by fasting hyperglycemia and by a high risk of atherothrombotic disorders affecting the coronary, cerebral, and peripheral arterial trees.[12] Despite improvement in the management of patients with unstable coronary syndromes, diabetes is still linked to a substantial increase in mortality and morbidity among these patients.[13] Accordingly, developing new therapies for the treatment of diabetic patients is of great clinical importance.[14,15]

In diabetes, dysfunction of the vascular endothelium is regarded as an important factor in the pathogenesis of diabetic micro- and macroangiopathy.[8] There are three main sources contributing to endothelial dysfunction in diabetes: (1) hyperglycemia and its immediate biochemical sequelae directly alter endothelial function; (2) high glucose (HG), which influences endothelial cell functioning indirectly by the synthesis of growth factors and vasoactive agents in other cells and alters endothelial monolayer permeability; and (3) the components of the metabolic syndrome that can affect endothelial function.[8]

There are many signaling molecules involved in the pathogenesis of endothelial dysfunction. In the following paragraphs, recent studies on this topic, mainly focusing on the roles of arginase and reactive oxygen species (ROS), protein kinase C (PKC), and tumor necrosis factor (TNF), are addressed.

**ROLE OF ARGINASE AND REACTIVE OXYGEN SPECIES IN DIABETES-ASSOCIATED ENDOTHELIAL DYSFUNCTION**

Conditions contributing to diabetic vascular remodeling and dysfunction include the effects of oxidative stress and decreased NO bioavailability.[16-19] NO production by endothelial NOS (eNOS) is critically involved in maintaining the integrity and stability of the vascular endothelium, preventing platelet aggregation and leukocyte adhesion, and maintaining blood flow.[20] Availability of the semi-essential amino acid L-arginine is required for eNOS activity and NO production and is therefore essential for vascular integrity and function. Arginase is a hydrolytic enzyme, which converts L-arginine into urea and ornithine and exists as 2 isoforms: arginase I and II.[21] Whereas arginase I is a cytosolic enzyme, expressed at high levels in the liver, arginase II is a mitochondrial enzyme expressed primarily in the extrahepatic tissues, especially in the kidney. Knockdown of arginase I has been shown to restore NO signaling in the vasculature of old rats.[22] Both arginase I and II have been found in endothelial cells, arginase I being the dominant isoform.[23]

Arginase and eNOS compete for their common substrate, L-arginine. As such, increased arginase activity can lead to eNOS dysfunction.[23,24] We have shown that hepatic and vascular arginase activity is increased in diabetic rats and that arginase I expression and activity are increased in aortic endothelial cells exposed to HG.[24] TNF has also been shown to induce arginase activity.[25] Furthermore, arginase actions causing endothelial dysfunction, as indicated by decreased NO availability, are blocked by the Rho kinase inhibitor Y-27632.[26] Additionally, an inhibitor of arginase reversed diabetes-induced endothelial dysfunction in the coronary vessels of diabetic rats.[24] Also, arginase was found to mediate retinal inflammation in lipopolysaccharide (LPS)-induced uveitis.[21]

Taken together, these findings[21-26] suggest that arginase and RhoA may be mediators of diabetes-induced inflammatory effects in vascular disease. Apart from arginase, ROS also play an important role in vascular dysfunction in diabetes, although the source of their generation remains elusive. Overproduction of superoxide can lead to scavenging of NO and to its reduced bioavailability.[27,28] ROS have been implicated in increased arginase activity and expression. Indeed, arginase activation can cause uncoupling of eNOS by reducing the supply of L-arginine. The uncoupled eNOS uses molecular oxygen to produce superoxide, thereby further reducing NO and increasing ROS formation [Figure 1].

**IMPLICATION OF PROTEIN KINASE C**

An important glucose-induced alteration in cellular metabolism that may account for endothelial dysfunction...
is activation of PKC. Hyperglycemia causes de novo synthesis of diacylglycerol, leading to the activation of PKC, a pathway now demonstrated in all vascular tissues involved in diabetic complications.[29] Of interest, the adverse effects of elevated glucose levels on acetylcholine-induced relaxation of rabbit aorta and rat pial arterioles were restored by the addition of PKC-inhibitors.[30,31] Diabetes-induced translocation of PKC-alpha to renal membranes was associated with increased nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide generation.[32] It has been proposed that HG concentrations rather specifically activate the beta II isoform of PKC.[33] However, the PKC alpha isoform, which is activated by HG in bovine aortic endothelial cells, has also been suggested to play an important role in diabetes mellitus-associated endothelial dysfunction, since specific antisense or pharmacologic inhibition completely abolished the effects of HG on endothelial cell permeability.[34] The reported activity of PKC-alpha on endothelial permeability is at least partially mediated by inducing phosphorylation of p115RhoGEF,[35] a guanine nucleotide exchange factor (GEF) for Rho GTPase.[36] Because active RhoA is implicated in arginase induction,[24] it suggests that PKC-alpha might also be involved in regulation of arginase activity.

TUMOR NECROSIS FACTOR: A MOONLIGHTING CYTOKINE IN ENDOTHELIAL DYSFUNCTION

Human TNF is a 51-kDa homotrimERIC protein. TNF is generated as a membrane-bound precursor that is cleaved by the metalloproteinase family member TNF-alpha converting enzyme, giving rise to the soluble protein.[37] The main sources of the cytokine are activated macrophages and T cells. TNF binds to 2 different TNF receptors, TNF-R1 (55 kDa) and TNF-R2 (75 kDa), at least one of which is expressed in most somatic cells.[37] Soluble TNF has the highest affinity for TNF-R1, whereas membrane-bound TNF preferentially interacts with TNF-R2.[38] Apart from the ligand TNF, also the receptors exist as membrane-associated and soluble forms.[37] TNF-R1, but not TNF-R2, contains a death domain, which signals apoptosis upon the formation of the death-inducing signaling complex[37] Although not carrying a death domain, TNF-R2 has nevertheless been implicated in apoptosis regulation in microvascular endothelial cells.[39]

Spatially distinct from its receptor binding sites, TNF carries a lectin-like domain, recognizing specific oligosaccharides, such as N,N'-diacetylchitobiose and branched trimannoses,[40] which can be mimicked by the 17-amino acid circular TIP peptide (amino acid sequence: CGQRETPEGAEKPYC).[41] Three residues, namely, T105, E107, and E110, appear to be crucial for this activity. The TIP peptide exerts a lytic activity toward bloodstream forms of African trypanosomes,[41] which occurs upon binding to the oligosaccharides expressed in the variant-specific glycoprotein of the parasites. More importantly, the TIP peptide also increases sodium transport in lung microvascular endothelial cells.[42] Interestingly, the activities of the lectin-like domain of TNF cannot be inhibited by the soluble TNF receptors.[41]

TNF is one of the key inflammatory mediators that is expressed during a variety of inflammatory conditions and initiates the expression of an entire spectrum of inflammatory cytokines ranging from many interleukins to interferons.[43] It is suggested that inflammation is an effector of not only endothelial dysfunction, but also insulin resistance and atherosclerosis.[44] Under inflammatory conditions, TNF can increase the expressions of adhesion molecules, such as vascular cell adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1); and as such promote the adherence of monocytes.[45] Moreover, TNF can affect NO production by decreasing eNOS expression[46] and increase the production of ROS in neutrophils and endothelial cells through NAPH oxidase,[47] xanthine oxidase,[48] and uncoupled NOS.[49] The pivotal role of TNF in diabetes-induced endothelial dysfunction can also be manifested by the observation that endothelial function is close to normal in a TNF-knockout diabetic mouse model.[50]

The generation of TNF is increased during diabetes, and the cytokine has been shown to upregulate the expression of arginase in endothelial cells, which leads to endothelial dysfunction during ischemia reperfusion injury in mice.[25]
Recent studies have indicated that TNF can affect endothelial barrier integrity, by means of (1) inducing apoptosis of lung microvascular endothelial cells, which can contribute to the disruption of the endothelial barrier during acute lung injury and acute respiratory distress syndrome; (2) by inducing the production of ROS, and (3) by directly increasing endothelial permeability in a RhoA/ROCK-dependent manner. PKC-alpha activation was proposed to be involved in TNF-mediated increases in permeability of pulmonary microvascul endothelial monolayers. On the other hand, the lectin-like domain of TNF, mimicked by the TIP peptide, can increase endothelial monolayer resistance in the presence of bacterial toxins, by means of inhibiting listeriolysin-induced PKC-alpha activation, which in turn inhibits RhoA activation and myosin light chain phosphorylation. Moreover, the lectin-like domain of TNF can reduce ischemia-reperfusion–induced ROS generation in a lung transplantation model. As such, the lectin-like domain of TNF can potentially oppose the deleterious receptor-mediated activities of the cytokine on the endothelium.

**CONCLUSION**

The present communication has reviewed some recent studies on diabetes-induced endothelial dysfunction and has discussed the important roles of arginase, PKC and TNF in this complicated pathological condition. The interactions between these molecules and the proposed mechanism of diabetes-induced endothelial dysfunction are summarized in Figure 1. New insights into these mechanisms and into crucial targets of endothelial dysfunction in diabetes may lead to novel strategies for treatment in the future.

**REFERENCES**

1. World Health Organization fact sheet number 312. World Health Organization, 2009.
2. Brown WV. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. Am J Cardiol 2010;105:10L-3L.
3. Ulrich B. Diabetes and kidney disease. Nephrol Nurs J 2009;36:461.
4. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004;44:397-405.
5. Versari D, Daghini E, Virdis A, Ghidoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009;32:S314-21.
6. Félétou M, Vhanouthe PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291:H985-1002.
7. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AB, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiologic mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55.
8. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005;109:143-59.
9. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95.
10. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004;19:778-81.
11. Potenza MA, Gagliardi S, Nacci C, Carratu’ MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009;16:94-112.
12. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007;262:157-72.
13. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006;29:798-804.
14. The effect of intensive treatment of diabetes on the progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-85.
15. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-67.
16. De Vries AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhouset PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963-74.
17. Fioraliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, et al. Cardioprotective effects of a beta adrenergic receptor blocker in patients with diabetes: a randomized controlled trial. Am J Cardiol 2006;97:245-51.
18. Tawfik HE, El-Remessy AB, Matraaon S, Ma G, Caldwell RB, Caldwell RW. Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmcol Exp Ther 2006;319:386-95.
19. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr Pract 2006;12:60-2.
20. Caldwell RB, Zhang W, Romero MJ, Caldwell RW. Vascular dysfunction in retinopathy-an emerging role for arginase. Brain Res Bull 2010;81:303-9.
21. Zhang W, Baban B, Rojas M, Tofighs S, Virmans SK, Patel C, et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol 2009;175:891-902.
22. White AR, Royo S, Li D, Champion HC, Steppan J, Wang D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2007;49:120-7.5.
23. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
24. Gao X, Xu X, Belmadi S, Park Y, Tang Z, Feldman AM, et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2007;27:1209-7.5.
25. Shiga N, Hirano K, Hirano M, Nishimura J, Nawata H, Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005;96:1014-21.
26. Tsunobuchi H, Inoue T, Sonta T, Sato N, Sekiguchi N, Kobyasheki K, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005;39:444-52.
27. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, et al. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005;45:860-6.
28. Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995;9:241-5.
29. Smith AM, Pannell RM, Coleh RE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004;19:778-81.
30. Potenza MA, Gagliardi S, Nacci C, Carratu’ MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009;16:94-112.
31. Mayhan WG, Patel KP. Acute effects of glucose on reactivity of cerebral microcirculation: role of activation of protein kinase C. Am J Physiol 1995;269:H1297-302.
Yang, et al.: Novel mechanisms of endothelial dysfunction in diabetes

32. Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, et al. Inhibition of NADPH oxidase prevents acute changes in product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-9.

33. Kourocrova A, Eto M, Joch H, Volpe M, Lüscher TF, Cosentino F. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004;110:91-6.

34. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997;81:563-71.

35. Holinstat M, Mehta D, Kozasa T, Minshall RD, Malik AB. Protein kinase Calpha-induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement. J Biol Chem 2003;278:28793-8.

36. Chen Z, Singer WD, Sternweis PC, Sprang SR. Structure of the protein kinase C alpha. Nat Struct Mol Biol 2005;12:191-7.

37. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-67.

38. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 1998;95:570-5.

39. Lucas R, Garcia I, Donati YR, Fukami K, Yap FY, Sourris KC, et al. Inhibition of NADPH oxidase prevents acute changes in product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-9.

40. Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-8.

41. Lucas R, Magez S, De Leys R, Fransen L, Scheerlinck JP, Rampelberg M, et al. Mapping the lectin-like activity of tumor necrosis factor. Science 1987;237:1479-84.

42. Yang GH, Gorshkov B, White R, Sridhar S, Verin A, Chakraborty T, et al. Role of NADPH oxidase in the development and progression of heart failure. Circ Heart Fail 2002;5:132-40.

43. Downey JM, Omar B, Oostra H, McGord J. Superoxide dismutase therapy for myocardial ischemia. Free Radic Res Commun 1991;12:13-703-20.

44. Pritchard KA Jr, Groszek I, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995;77:510-8.

45. Gao X, Belmadani S, Pechi A, Xu X, Potter BJ, Tewari-Singh N, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007;115:254-55.

46. Yang GH, Gorshkov B, White R, Sridhar S, Verin A, Chakraborty T, et al. The role of xanthine oxidase and reactive oxygen intermediates in LPS- and TNF-induced pulmonary edema. J Lab Clin Med 1994;123:394-9.

47. Petrochle I, Bittkova A, Ramirez SI, Garcia JG, Verin AD. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am J Respir Cell Mol Biol 2003;28:574-81.

48. Ferro T, Neumann P, Gertzberg N, Clements R, Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol 2000;278:L1107-17.

49. Braun C, Haracher J, Morel DR, Wendel A, Lucas R. Dichotomal role of protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-9.

50. Nishio C, Yang G, Kumar S, Aggarwal S, Nead C, et al. The lectin-like domain of tumor necrosis factor protects from lectin-like-domain-induced hyperpermeability in human pulmonary microvascular endothelial cells - A crucial role for protein kinase C-alpha inhibition. Vascul Pharmacol 2010;52:207-13.

51. Haracher J, Stammberger U, Roux J, Kumar S, Yang G, Xiong C, et al. The lectin-like domain of tumor necrosis factor improves lung function after endotoxemia. J Immunol 2005;175:3402-8.

52. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008;103:398-406.

53. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009;120:1266-86.

54. Deisher TA, Hadclit TL, Montgomery KE, Pohlman TH, Kaushansky K, Harlan JM. The role of protein kinase C in the induction of VCAM-1 expression on human umbilical vein endothelial cells. FEMS Lett 1993;331:285-90.

55. MacNeau KL, Hutsheinon NI. Differential expression of iNOS and eNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 1993;196:1330-4.

56. Schmid P, Lyseng-Scott M, Aggarwal S, Nead C, et al. The lectin-like domain of tumor necrosis factor protects from lectin-like-domain-induced hyperpermeability in human pulmonary microvascular endothelial cells - A crucial role for protein kinase C-alpha inhibition. Vascul Pharmacol 2010;52:207-13.

57. Haracher J, Stammberger U, Roux J, Kumar S, Yang G, Xiong C, et al. The lectin-like domain of tumor necrosis factor improves lung function after endotoxemia. J Immunol 2005;175:3402-8.